About This Survey

The subject

Ascent Peptides surveys the published research on three peptides studied for the growth hormone axis: CJC-1295, Sermorelin, and Tesamorelin, with CJC-1295 as the lead. The point is to make a scattered and frequently overstated literature legible — to tell a reader, in plain language and with citations, what each GHRH analog was actually studied for, in which populations, and how far that evidence reaches.

The organizing frame is the GH-axis secretagogue class: three compounds that share a receptor target (the pituitary GHRH receptor) and a basic mechanism (upstream stimulation of the GH/IGF-1 axis), yet diverge sharply in their structural durability strategies, their half-lives, and the depth of their human evidence. Reading them as a group shows both what the class can do in principle and where each compound's evidence actually ends. Each compound has its own page; a comparison page ranges them side by side; and a single shared references list gathers every source.

The survey's ground rules

Three rules shape the survey.

Everything rests on the peer-reviewed literature. Every research claim carries a numbered citation — PubMed-indexed articles, reviews, and official monographs — collected on the references page. A finding that comes from a review or editorial, rather than a primary study, is cited as such, with its status as secondary commentary noted.

Evidence is stated at its true strength. Doses and outcomes appear in the species and context where they were studied — "raised mean GH 2- to 10-fold in healthy adults" or "reduced visceral fat in HIV-infected adults on antiretroviral therapy" — never scaled into general recommendations. Where an approved indication exists, it is described in its approved terms; off-label questions are framed as research questions. Where an editorial explicitly cautions against a use, that caution runs up front, not in a footnote.

The three pages talk to each other. Because the same receptor, the same GH/IGF-1 axis, and the same DPP-IV stability problem recur across all three, the pages link together so a reader can trace a design choice or an evidence gap from one analog to the next.

The boundaries

Ascent Peptides is not a store, not a clinic, and not a source of medical advice. Nothing is sold, supplied, sourced, or brokered here — no peptide, no research chemical — and no affiliate or referral tie connects it to any vendor. No clinicians staff these pages, no conditions are diagnosed, and nothing is prescribed; no dose, schedule, or route is named for anyone.

The peptides here are research compounds or, in tesamorelin's case, a prescription drug approved for a specific indication. None is an over-the-counter supplement, and several are expressly prohibited in sport. A reader drawn to any condition in the underlying research should consult a licensed clinician in their own jurisdiction, working from regulated, evidence-based options. What the site offers is a careful reading of the research literature — and nothing it isn't.